Literature DB >> 759652

Esophageal carcinoma presenting as a primary renal tumor.

R E Marsan, D A Baker, M E Morin.   

Abstract

A patient with esophageal carcinoma presenting with hematuria is described. Initial studies confirmed the presence of a renal mass that was thought to be a primary renal neoplasm. Further studies to evaluate anemia before a renal operation led to the discovery of an unsuspected esophageal carcinoma. Although metastases to the kidneys are relatively common it is uncommon for these lesions to be clinically apparent or responsible for producing initial symptomatology. Only after discovery of the esophageal lesion was the possibility of a secondary renal neoplasm considered. Intractable hematuria was treated successfully by embolizing the renal artery of the bleeding kidney with gelatin sponge fragments.

Entities:  

Mesh:

Year:  1979        PMID: 759652     DOI: 10.1016/s0022-5347(17)56675-6

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  4 in total

1.  Esophageal adenocarcinoma with solitary renal metastasis.

Authors:  Thomas D Willson; Matthew J Blecha; Mark M Connolly; Francis J Podbielski
Journal:  J Gastrointest Cancer       Date:  2013-09

2.  Esophageal squamous cell carcinoma recurring as a solitary renal mass.

Authors:  Do Hyoung Lim; Young-Hyuck Im; Sang Hoon Ji; Byeong-Bae Park; Mi Jung Oh; Jeeyun Lee; Keun Woo Park; Se-Hoon Lee; Joon-Oh Park; Kihyun Kim; Won Seog Kim; Chul Won Jung; Young Suk Park; Won Ki Kang; Mark H Lee; Kwanmien Kim; Young Mog Shim; Keunchil Park
Journal:  Cancer Res Treat       Date:  2004-08-31       Impact factor: 4.679

3.  Haematuria as a presentation of metastatic oesophageal carcinoma.

Authors:  R Hargunani; S Al-Dujaily; Aks Abdulla; Dr Osborne
Journal:  Int Semin Surg Oncol       Date:  2005-02-20

4.  Synchronous and metachronous metastasis to renal parenchyma of esophageal squamous cell carcinoma: two case reports and review of the literature.

Authors:  Jun Jia; Wei Sun; Dongmei Lin; Xiaodong Zhang
Journal:  Transl Cancer Res       Date:  2021-02       Impact factor: 1.241

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.